|
|
Novartis Ag's Yearly Income from Continued Operations Growth 5 Years |
|
Select the Comparisons :
|
|
Select the Ratio:
|
Annual Income from Cont. Operations Annual Growth Rates Y/Y▼
|
Annual Income from Cont. Operations Annual Growth Rates Y/Y▼
|
NVS Annual Income from Cont. Operations Growth |
2023
|
2022
|
2021
|
2020
|
2019
|
Y / Y Annual Income from Cont. Operations Change |
113.57 % |
-71.04 % |
197.58 % |
-31.23 % |
-6.95 % |
Annual Income from Cont. Operations (in millions $) |
$14,854.00 |
$6,955.00 |
$24,018.00 |
$8,071.00 |
$11,737.00 |
Annual Income from Cont. Operations Growth
Comment |
Novartis Ag's Annual Income from Cont. Operations for the fiscal year ended 2023, more than doubled to 113.57% to $14,854.00 millions, from $6,955.00 millions achieved a year ago. Novartis Ag's growrh rate for Income from Continued Operations improved from -71.04 % decline in the fiscal year 2022.
Novartis Ag Annual Income Statement
|
You need to upgrade your Flash Player
|
Companies with similar 2023 Annual Income from Cont. Operations within Healthcare Sector | Y/Y Income from Continued Operations Growth % | 2023 Annual Income from Cont. Operations | Pfizer Inc | -93.08 % | $ 2,173.000 millions | Abbvie inc | -58.86 % | $ 4,873.000 millions | Sanofi | -35.93 % | $ 6,088.320 millions | Moderna Inc | | | |